Please login to the form below
Janssen
This page shows the latest Janssen news and features for those working in and with pharma, biotech and healthcare.
BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
efficacy against Janssen’s Imbruvica (ibrutinib) in patients with relapsed/refractory CLL or SLL, as well as against bendamustine plus rituximab in treatment-naïve CLL or SLL patients.
Latest news
-
Janssen’s Imbruvica shows promise in chronic lymphocytic leukaemia study
The Janssen Pharmaceutical Companies of Johnson &Johnson (Janssen) have shared results from a real-world study evaluating the use of Imbruvica (ibrutinib) in patients with chronic lymphocytic leukaemia (CLL). ... medical affairs, oncology, Janssen Biotech
-
Cancer Research Horizons and Newcastle University extend alliance with Astex
Astex subsequently entered into a drug discovery collaboration and licence agreement on FGFR inhibitors with Janssen – a pharmaceutical arm of Johnson &Johnson – which resulted in the identification of Balversa (erdafitinib), approved
-
GSK’s ViiV submits application for cabotegravir to EMA for HIV-1 prevention
The company recently presented positive results from a phase 3b study which showed the combination of cabotegravir with Janssen’s – a pharmaceutical arm of Johnson &Johnson – Rekambys (rilpivirine long-acting injectable
-
Janssen’s Tecvayli granted FDA approval for multiple myeloma
Janssen – a pharmaceutical arm of Johnson &Johnson – has announced that Tecvayli (teclistamab-cqyv) has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with ... We are greatly encouraged by the FDA’s
-
Janssen’s Erleada combination accepted in Scotland for prostate cancer
The combination therapy significantly improved progression-free and overall survival rates. Janssen – a pharmaceutical arm of Johnson &Johnson – has announced that Erleada (apalutamide), in combination with androgen deprivation therapy (ADT),
More from news
Approximately 158 fully matching, plus 423 partially matching documents found.
Latest Intelligence
-
The importance of value when treating patients
Jennifer Lee is Therapy Area Market Access Leader for Janssen EMEA.
-
Customers, content and change
Personalisation was also cited as one of three key trends shaping the future of our industry, along with commercial excellence and flexibility, by Janssen’s Maria Raad, Janssen EMEA’s vice
-
How diversity and inclusion continues to be incorporated in dermatology
3. Janssen, as part of the pharmaceutical companies of Johnson &Johnson, has a 130-year heritage in healthcare. ... When it comes to decision-making in dermatological R&D, Janssen works with patients to enshrine the patient voice.
-
My journey advancing the science in pulmonary hypertension
It’s exactly how we are at Janssen now, and I am thankful to have a team dedicated to driving the science forwards. ... Neil Davie is Head of Late Development, Cardiovascular, Metabolism &Pulmonary Hypertension at the Janssen Pharmaceutical Companies
-
Paving the way for representation in clinical trials
Lee-Ann Farrell comments: “I’m committed to championing all DE&I efforts throughout Janssen. ... References are available on request. This article has been commissioned by, and developed by, Janssen-Cilag Ltd.
More from intelligence
Approximately 5 fully matching, plus 59 partially matching documents found.
Latest appointments
-
Genmab appoints Tahamtan Ahmadi as chief medical officer, head of experimental medicines
Prior to Genmab, Ahmadi worked as head of experimental medicine and early development oncology at Janssen.
-
Ex-J&J exec Denice Torres joins bluebird bio’s board
During her time at J&J, Torres held several executive leadership roles including president of McNeil Consumer Healthcare and president of Janssen Pharmaceuticals, CNS.
-
New hires at Bristol-Myers Squibb, Acceleron and FerGene
He has also served in various executive leadership roles at Novartis Pharma and Novartis Oncology, and he began his career at Johnson &Johnson and Janssen.
-
Robert Freisen joins Ablynx
He has previously held roles for ProQR Therapeutics, Janssen BioTherapeutics, and MorphoSys.
-
Mundipharma appoints Dr Alberto Martinez as president and CEO
Prior to his time at Mundipharma, he served Napp Pharmaceuticals and Janssen in various capacities.
More from appointments
Approximately 3 fully matching, plus 27 partially matching documents found.
Latest from PMHub
-
FREE WEBINAR: End-to-end patient strategy: making a treatment for patients, with patients
Our first confirmed speaker is Daniel de Schryver, Patient Engagement &Advocacy Lead, Europe, Middle-East and Africa, Janssen.
-
The Difference Collective
Copywriting. AKLRD | A Life in a Day | Allergan | Amgen | Arquer Diagnostics | Bleepa | Boehringer Ingelheim | Galapagos | Inivata | Janssen | Kantar | Maxwellia | Macmillan | Mundipharma | Norgine | Novo Nordisk | Pfizer | Roche | Sanofi | Santen |
-
VISFO invests in a new brand as it continues to grow its client base in the US and Europe
Working with global pharma clients such as Takeda, GSK, Janssen and Abbvie, the consultancy is on a trajectory for growth and has doubled in size due to its commitment to technology,
-
What does the future hold for Light-chain Amyloidosis?
Recently, Darzalex (daratumumab), a monoclonal antibody developed by Genmab and Janssen, that has been available for the management of patients with multiple myeloma across Europe for 5 years, was granted accelerated
-
OPEN Health’s Learning & Development team have won a Bronze Award at the PM Society Digital Awards 2020
READ MORE ABOUT OUR WINNING PROJECT WITH WITH JANSSEN BELOW:. The Immunology Training Summit (ITS) 2020 with the Janssen EMEA Immunology team took a week-long face-to-face meeting for ... Strikingly this format is now considered best practice in
More from PMHub
Approximately 5 fully matching, plus 31 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- Europe’s cancer community publishes new report on transforming patient care
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- EU outlines measures to mitigate antibiotic shortage across Europe
- Sanofi/Regeneron’s Dupixent recommended by CHMP for atopic dermatitis in children
- Bristol Myers Squibb’s plaque psoriasis treatment recommended by CHMP
- Sandoz’s high concentration Hyrimoz formulation recommended for use in EU
- ASH 2022: bad blood but big advances
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- Alzheimer’s Society urges UK government to deliver on dementia plan
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Sanofi backs vaccines unit with €350m Canadian facility
- World Health Organization releases latest set of COVID-19 guidelines
- Omnichannel communications in Medical Affairs: closing the gap between aspiration and reality
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- ASH 2022: bad blood but big advances
- Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
